Agenus’ (AGEN) Buy Rating Reaffirmed at Chardan Capital

Agenus (NASDAQ:AGEN)‘s stock had its “buy” rating reiterated by research analysts at Chardan Capital in a research report issued on Thursday, Benzinga reports.

Several other analysts also recently weighed in on AGEN. Rodman & Renshaw began coverage on Agenus in a research note on Monday, September 28th. They set a “buy” rating and a $19.00 target price for the company. Wall Street Zen downgraded Agenus from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 17th. HC Wainwright restated a “buy” rating and set a $25.00 target price (down from $30.00) on shares of Agenus in a research note on Tuesday, August 11th. B. Riley Financial restated a “buy” rating and set a $14.00 target price (up from $8.00) on shares of Agenus in a research note on Thursday, July 30th. Finally, Weiss Ratings upgraded Agenus from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, October 8th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Agenus currently has an average rating of “Moderate Buy” and an average price target of $24.50.

Agenus Trading Up 1.0%

NASDAQ:AGEN traded up $0.07 on Thursday, reaching $6.47. The stock had a trading volume of 135,904 shares, compared to its average volume of 1,874,983. The company has a 50-day moving average of $7.71 and a 200 day moving average of $5.48. The stock has a market cap of $292.02 million, a P/E ratio of 2.51 and a beta of 1.31. Agenus has a 12-month low of $2.71 and a 12-month high of $10.31.

Agenus (NASDAQ:AGEN) last announced its earnings results on Friday, August 7th. The biotechnology company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.06). The business had revenue of $34.52 million for the quarter, compared to analyst estimates of $34.00 million. Agenus had a net margin of 69.33% and a negative return on equity of 47.68%. On average, equities analysts predict that Agenus will post -0.30 EPS for the current year.

Hedge Funds Weigh In On Agenus

A number of hedge funds have recently bought and sold shares of the company. Everhart Financial Group Inc. acquired a new position in Agenus in the third quarter worth about $100,000. Bank of New York Mellon Corp acquired a new position in Agenus in the second quarter worth about $311,000. Bank of America Corp DE grew its stake in Agenus by 796.7% in the first quarter. Bank of America Corp DE now owns 118,782 shares of the biotechnology company’s stock worth $397,000 after purchasing an additional 105,536 shares in the last quarter. Finally, Globeflex Capital L P acquired a new position in Agenus in the second quarter worth about $1,281,000. 61.46% of the stock is currently owned by institutional investors and hedge funds.

About Agenus

Agenus Inc (NASDAQ: AGEN) is a biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research programs are designed to activate and strengthen the immune system’s ability to recognize and attack tumors, with an emphasis on therapies that may be used alone or in combination.

Agenus’ pipeline includes botensilimab, an investigational Fc-enhanced CTLA-4 antibody, and balstilimab, an investigational PD-1 inhibitor. The company has studied these therapies in combination across several solid-tumor indications, including colorectal cancer and other advanced cancers.